Shingrix Side Effects
Shingrix commonly causes injection site pain (75-88%), fatigue (37-64%), myalgia (37-58%), headache (15-44%), and fever (6-28%), with most reactions being mild to moderate and resolving within 1-3 days. 1
Local Reactions (Within 7 Days of Vaccination)
The most frequent local adverse reactions include:
- Pain at injection site: 75-88% of recipients (Grade 3 pain preventing normal activities: 5-11%)
- Redness: 20-35% of recipients
- Swelling: 10-21% of recipients 1
These local reactions typically persist for 1-3 days and are significantly more common than with placebo (6-8% pain rate) 1.
Systemic Reactions (Within 7 Days of Vaccination)
Common systemic adverse reactions include:
- Fatigue: 37-64% (Grade 3: 3-10%)
- Myalgia: 37-58% (Grade 3: 2-8%)
- Headache: 15-44% (Grade 3: 0.1-5%)
- Shivering: 11-31% (Grade 3: 0.4-6%)
- Fever ≥37.5°C/99.5°F: 6-28%
- Gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal pain): 13-21% 1
The second dose tends to produce more systemic reactions than the first dose, particularly for myalgia, headache, and shivering 1.
Age-Related Differences
Younger adults (18-49 years) experience slightly higher rates of systemic reactions compared to those ≥50 years, though the differences are modest. Both age groups show similar local reaction profiles 1.
Serious Adverse Events
Serious adverse events are uncommon:
- Reported in 6.6% overall (2.9% for Shingrix in immunocompetent populations, higher in immunocompromised groups at 7%)
- Anaphylaxis: approximately 1 per 600,000 doses
- Guillain-Barré syndrome: No confirmed increased risk in large post-licensure surveillance studies 2, 3
- Deaths and serious events in clinical trials occurred at similar or lower rates compared to placebo 1
Special Populations: Immunocompromised Adults
In immunocompromised populations (including hematopoietic stem cell transplant recipients, patients with hematologic malignancies, renal transplant recipients, HIV-infected individuals, and those receiving chemotherapy), the side effect profile remains similar to immunocompetent adults, though monitoring is important:
- Unsolicited adverse events within 30 days: 46% (vs 44% placebo)
- Serious adverse events: 7% (vs 8% placebo)
- No increased risk of disease relapse, progression, or transplant rejection was observed 1
Rare but Reported Adverse Events
Post-marketing surveillance and case reports have identified rare potential associations:
- Vaccine-induced lupus: One documented case with positive ANA and anti-cardiolipin antibodies that resolved with corticosteroids 4
- Prolonged neurological/musculoskeletal symptoms: Rare cases of persistent joint pain, numbness, and tingling lasting >1 year 5
- Paradoxical herpes zoster: Rare cases of HZ developing within 72 hours post-vaccination, possibly from VZV reactivation or immune-mediated response 6, 7
These remain exceedingly rare and require further investigation to establish causality 2.
Important Clinical Context
Reactogenicity should not be confused with lack of safety. The adjuvanted nature of Shingrix (containing AS01B) is designed to enhance immune response, which inherently produces more local and systemic reactions compared to non-adjuvanted vaccines 8, 9. However, large-scale post-licensure surveillance of 647,833 doses confirmed no sustained increased risk of monitored serious outcomes 3.
Co-administration considerations: When Shingrix is given with other adjuvanted vaccines, consider using a non-adjuvanted influenza vaccine option if administered concomitantly, though vaccination should not be delayed if specific products are unavailable 8, 9.
Management Recommendations
For patients concerned about side effects:
- Premedication with acetaminophen or NSAIDs can be considered for the second dose if the first dose caused significant discomfort, though this is not routinely necessary
- Schedule vaccination when patients can rest for 1-2 days if needed
- Reassure patients that reactions typically resolve within 1-3 days
- The second dose should still be administered despite reactions to the first dose, as the two-dose series is necessary for optimal protection 10, 1
The benefits of Shingrix in preventing herpes zoster and its complications, particularly post-herpetic neuralgia, substantially outweigh the risk of these generally mild and transient adverse reactions 10, 11, 12.